^
    Back
    Association details:
    Biomarker:p95HER2 mutation
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    SABCS 2022
    Title:

    P95HER2 Expression in HER2-Positive Breast Cancer

    Published date:
    11/22/2022
    Excerpt:
    We assessed 68 HER2-positive patients (IHC 3+ or IHC 2+/in situ hybridization [ISH]+) from Fudan University Shanghai Cancer Center (FUSCC) who underwent breast cancer surgery and were treated with adjuvant chemotherapy (taxane or anthracycline or combination) plus trastuzumab from 2014 to 2016....P95HER2 positive expression (P= 0.033) were associated with worse DDFS.
    Secondary therapy:
    Chemotherapy